Therapy Directory

Tirzepatide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention. Browse Tirzepatide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

178

Shown on this page

Local indexed summaries

Local recruiting

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Showing 1–12 of 178 matching trials for Tirzepatide.

Live ClinicalTrials.gov results.

Top conditions

Obesity 31 Overweight 11 Type 2 Diabetes 5 Endometrial Cancer 3 Obesity & Overweight 3 Obesity and Overweight 3

Top sponsors

Eli Lilly and Company 17 The Cleveland Clinic 3 Brigham and Women's Hospital 2 Johns Hopkins University 2 M.D. Anderson Cancer Center 2 Massachusetts General Hospital 2

Top locations

Chicago, Illinois 15 Houston, Texas 13 New York, New York 12 Miami, Florida 11 Los Angeles, California 10 San Antonio, Texas 10

Live official records

Open in full search

Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions: eloralintide and tirzepatide, Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 25
States / cities: Tucson, Arizona • Los Alamitos, California • Los Angeles, California + 20 more

Conditions: Type 2 Diabetes
Interventions: Cagrilintide, Semaglutide, Tirzepatide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,024 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 117
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 96 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Cagrilintide, Semaglutide, Tirzepatide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,023 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 54
States / cities: Pelham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more

Conditions: Obesity
Interventions: eloralintide and tirzepatide, Eloralintide, Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 2,115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 55
States / cities: Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 45 more

Conditions: Overweight, Obesity, Type 2 Diabetes
Interventions: Tirzepatide, Zenagamtide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Post-Bariatric Hypoglycemia
Interventions: Dietary Intervention, GLP-1 receptor agonist or Dual GIP/GLP-1 receptor agonist, Transoral Outlet Reduction (TORe); Behavioral · Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
Interventions: Semaglutide, Berobenatide, Tirzepatide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 13 more

Conditions: Sarcoma,Soft Tissue
Interventions: Tirzepatide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 39 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alcohol Use Disorder (AUD)
Interventions: Tirzepatide, Placebo, [11C]raclopride plus drug, [11C]NNC-112; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 41
States / cities: Tucson, Arizona • Loma Linda, California • Los Angeles, California + 33 more

Conditions: Type 2 Diabetes
Interventions: LY3457263, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Santa Ana, California • Ocala, Florida + 21 more

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions: Tirzepatide, Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 4,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 141
States / cities: Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 122 more

About this Tirzepatide clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Tirzepatide.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Tirzepatide clinical trials

Filter and sort this therapy

Top conditions

Top sponsors

Top locations

Live official records

A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication

Dietary, Medication, and Endoscopic Interventions for Post-Bariatric Hypoglycemia

A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study

Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

About this Tirzepatide clinical trials directory page